HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

198.400

+6.4003.33%

Volume:85.27K

Turnover:16.92M

Market Cap:15.62B

PE:66.58

High:201.800

Open:196.000

Low:192.100

Close:192.000

52wk High:302.400

52wk Low:97.500

Shares:78.71M

HK Float Shares:78.71M

Volume Ratio:0.90

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(LYR):2.980

ROE:16.58%

ROA:9.23%

PB:8.01

PE(LYR):66.58

PS:22.50

Loading ...

Overview Company News Filings

Fujian Haixi Pharma Gets Positive Data from Two Trials of Macular Degeneration Drug

MT Newswires Live

Haixi Pharma Unveils Encouraging Early-Stage Clinical Results for HX9428 in Treating Wet AMD

HAIXI PHARMA Reports Positive 24-Week Phase I Results and Interim Phase II Progress for Oral nAMD Candidate HX9428

Bulletin Express

港股市场动态：海西新药股价上扬，新药申请获受理推进

Fujian Haixi Pharma Submits China IND for Hx9428 Phase IIa Trial in Diabetic Macular Edema

Fujian Haixi Pharma FY26 H1 Net Profit Falls 24.82% to RMB 81.05 Million; Revenue Rises 3.85% to RMB 311.62 Million

Humanoid Robot Output Ramps Up as Oil and Gas 15th Five-Year Plan Takes Shape

HAIXI PHARMA Gains US FDA Fast Track Status for Lead Candidate Targeting Wet AMD

Fujian Haixi Pharma Says FDA Grants Fast Track Status to Hx9428 for Wet AMD

Fujian Haixi Pharmaceuticals Co - Hx9428 Granted Fast Track Designation by U.S. FDA for Neovascular Age-Related Macular Degeneration

THOMSON REUTERS

Haixi Pharma Sets 28 Aug 2026 Board Meeting to Approve 1H26 Results and Discuss Interim Dividend

Bulletin Express

Fujian Haixi Pharmaceuticals Schedules Board Meeting to Review Interim Results

Haixi Pharma Discloses Detailed Rationale and Timeline for Replacing Deloitte with RSM as External Auditor

Bulletin Express

Fujian Haixi Pharma Clarifies Auditor Switch Driven by CASBE Reporting Demands, not Deloitte Dispute

Fujian Haixi Jumps on Initial Approval of Hx9428 for Macular Degeneration Treatment

Haixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428

Haixi Pharma secures FDA clearance for HX9428 Phase II nAMD trial and launches parallel study in China

Bulletin Express

HAIXI PHARMA Advances Oral nAMD Treatment with FDA Trial Approval and New Chinese Study

Fujian Haixi Pharma Wins FDA IND Clearance for Hx9428 Phase II nAMD Trial

Fujian Haixi Pharmaceuticals Co - U.S. FDA Approves Ind Application of Hx9428 for Neovascular Age-Related Macular Degeneration

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/02637/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":198.4,"timestamp":1789546126006,"preClose":192,"halted":0,"volume":85268,"delay":0,"changeRate":0.03333333333333336,"floatShares":78707270,"shares":78707270,"eps":2.9796610967286417,"marketStatus":"Not Yet Opened","change":6.4,"latestTime":"09-16 16:08:46","open":196,"high":201.8,"low":192.1,"amount":16923890,"amplitude":0.050521,"askPrice":199.5,"askSize":50,"bidPrice":198.4,"bidSize":450,"shortable":3,"etf":0,"ttmEps":2.333237059480662,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":192,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":0.896237,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.979661,"volumeRatio":0.896237,"shares":78707270,"dividePrice":0,"high":201.8,"amplitude":0.050521,"preClose":192,"low":192.1,"week52Low":97.5,"pbRate":"8.01","psRate":"22.50","week52High":302.4,"institutionHeld":0,"latestPrice":198.4,"committee":0.8,"eps":2.9796610967286417,"divideRate":0,"volume":85268,"delay":0,"ttmEps":2.333237059480662,"open":196,"prevYearClose":136,"prevWeekClose":193,"prevMonthClose":192,"prevQuarterClose":180,"fiveDayClose":192.3,"twentyDayClose":200,"sixtyDayClose":160},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-09-15","current":85.03208,"percent":0.864865,"low":41.43616,"twenty":68.545808,"median":72.645218,"eighty":81.246438,"high":108.687128,"avg":74.536737,"sd":9.343152,"marketCap":15111795840},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270},{"date":"2026-08-28","current":74.907011,"twenty":68.42835,"median":72.201471,"eighty":78.768036,"marketCap":15465978555},{"date":"2026-09-04","current":89.46632,"twenty":68.54394,"median":72.352576,"eighty":79.884165,"marketCap":15686358911},{"date":"2026-09-11","current":86.521471,"twenty":68.545014,"median":72.521094,"eighty":80.616434,"marketCap":15190503110},{"date":"2026-09-15","current":86.087181,"twenty":68.545808,"median":72.645218,"eighty":81.246438,"marketCap":15111795840}],"updateTime":1789586305308},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667985517","title":"Fujian Haixi Pharma Gets Positive Data from Two Trials of Macular Degeneration Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667985517","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667985517?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:54","pubTimestamp":1789563247,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals  obtained clinical data from the phase I and II clinical studies of HX9428 for the treatment of neovascular age-related macular degeneration.In the phase I study, the drug demonstrated an improving trend in visual function and macular anatomical parameters.Overall tole ratability was favorable and no dose-limiting toxicity was observed at any dose level.In the ongoing phase II dose expansion trial, the overall efficacy trend was consistent with the results of the phase I study, with favorable overall tolerability.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123675460","title":"Haixi Pharma Unveils Encouraging Early-Stage Clinical Results for HX9428 in Treating Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=1123675460","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123675460?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:32","pubTimestamp":1789561938,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has reported that its Phase I clinical trial in China evaluating HX9428 for neovascular age-related macular degeneration (nAMD) has completed the 24-week treatment observation...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178758772","title":"HAIXI PHARMA Reports Positive 24-Week Phase I Results and Interim Phase II Progress for Oral nAMD Candidate HX9428","url":"https://stock-news.laohu8.com/highlight/detail?id=1178758772","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178758772?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:24","pubTimestamp":1789561456,"startTime":"0","endTime":"0","summary":"Hong Kong-listed HAIXI PHARMA announced updated clinical data for HX9428, its orally administered small-molecule therapy under development for neovascular age-related macular degeneration (nAMD)....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191881847","title":"港股市场动态：海西新药股价上扬，新药申请获受理推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1191881847","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191881847?lang=en_us&edition=fundamental","pubTime":"2026-09-15 14:52","pubTimestamp":1789455138,"startTime":"0","endTime":"0","summary":"港股市场上，海西新药 (02637)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBJ","IBBQ","MDTX","BK1191","BMED","02637","BK4588","BK4585","VXUS","KCAI","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664807816","title":"Fujian Haixi Pharma Submits China IND for Hx9428 Phase IIa Trial in Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2664807816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664807816?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:17","pubTimestamp":1788347858,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma submits China IND for HX9428 Phase IIa trial in diabetic macular edemaFujian Haixi Pharmaceuticals submitted a China IND to start a Phase IIa trial of oral eye drug HX9428 in diabetic macular edema.Filing was made to the NMPA’s Center for Drug Evaluation on Aug. 31, 2026, adding a second indication to the program.HX9428 previously received FDA Fast Track designation; Phase II trials in wet age-related macular degeneration are ongoing in China and the US.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on September 02, 2026, and is so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLbtCW0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662093317","title":"Fujian Haixi Pharma FY26 H1 Net Profit Falls 24.82% to RMB 81.05 Million; Revenue Rises 3.85% to RMB 311.62 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662093317","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662093317?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:44","pubTimestamp":1787921097,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma FY26 H1 net profit falls 24.82% to RMB 81.05 million; revenue rises 3.85% to RMB 311.62 millionFujian Haixi Pharmaceuticals posted net profit of RMB 81.05 million, down 24.82% year","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL1DVYVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197788123","title":"Humanoid Robot Output Ramps Up as Oil and Gas 15th Five-Year Plan Takes Shape","url":"https://stock-news.laohu8.com/highlight/detail?id=1197788123","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197788123?lang=en_us&edition=fundamental","pubTime":"2026-08-18 07:44","pubTimestamp":1787010282,"startTime":"0","endTime":"0","summary":"Humanoid Robot Mass Production Accelerates Significantly; Unitree IPO Set to Reshape Valuation of Core ManufacturersOn August 12, Unitree Technology (688836.SH) announced that its bionic bipedal...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DIG","SG9999002950.SGD","VXUS","BK1144","FCG","QGmain","02432","DRLL","BK1161","BK1170","DRIP","UNG","OILU","XLE","USOI","BK1183","LU0227179875.USD","PXE","UGAZ","BNO","OILK","PXJ","IXC","KOLD","DUG","OILT","XES","BOIL","159019","BK4570","OIH","ROBO","PBOT","USL","02285","ERX","00179","BK1191","NGmain","LU0196878994.USD","KCAI","06990","06613","BK4585","DGAZ","FTXN","VDE","XOP","MNGmain","02637","DBE","KOMP","IEO","BK1214","USE","DBC","GUSH","WTIU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144208033","title":"HAIXI PHARMA Gains US FDA Fast Track Status for Lead Candidate Targeting Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=1144208033","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144208033?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:54","pubTimestamp":1786967655,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced that its independently developed innovative drug candidate, HX9428, from the HXP056 project, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK1191","02637","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482951","title":"Fujian Haixi Pharma Says FDA Grants Fast Track Status to Hx9428 for Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482951","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482951?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:45","pubTimestamp":1786967146,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma says FDA grants fast track status to HX9428 for wet AMDFujian Haixi Pharmaceuticals’ oral small-molecule HX9428 won FDA Fast Track designation for neovascular age-related macular d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL9VVlkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660829884","title":"Fujian Haixi Pharmaceuticals Co - Hx9428 Granted Fast Track Designation by U.S. FDA for Neovascular Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2660829884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660829884?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:45","pubTimestamp":1786967139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44E0EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178678659","title":"Haixi Pharma Sets 28 Aug 2026 Board Meeting to Approve 1H26 Results and Discuss Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1178678659","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178678659?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:04","pubTimestamp":1786529042,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) has scheduled a board meeting for Friday, 28 August 2026. The agenda includes: • Reviewing and approving the Group’s interim financial results...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658297306","title":"Fujian Haixi Pharmaceuticals Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658297306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658297306?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:40","pubTimestamp":1786527632,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals schedules board meeting to review interim resultsFujian Haixi Pharmaceuticals will hold a board meeting on Aug. 28, 2026 to review interim results for the six months ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3QX4V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196822915","title":"Haixi Pharma Discloses Detailed Rationale and Timeline for Replacing Deloitte with RSM as External Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=1196822915","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196822915?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:25","pubTimestamp":1786451154,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) issued a supplemental announcement clarifying the sequence of events and assessments that led to the appointment of RSM China CPA LLP...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992625","title":"Fujian Haixi Pharma Clarifies Auditor Switch Driven by CASBE Reporting Demands, not Deloitte Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992625","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992625?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:12","pubTimestamp":1786446743,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma clarifies auditor switch driven by CASBE reporting demands, not Deloitte disputeFujian Haixi Pharmaceuticals issued a supplemental clarification on its proposed auditor change, citing rising PRC demands for CASBE-based audit reports.Requests came from a local industry bureau on April 22, then China Merchants Bank on June 1 and Industrial Bank on June 2.The board framed the switch as a move to adopt CASBE as the primary reporting framework, avoiding dual IFRS and CASBE audits.It said the change was not driven by audit quality issues at Deloitte, noting no disagreements or unresolved matters.RSM began interim review work for the six months ended June 30, with a review report targeted for Aug. 28.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL5Q3Ld2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0229945570.USD","LU0456827905.SGD","LU2495084118.USD","LU0821914370.USD","BK0278","LU2213484517.USD","LU1580142542.USD","LU0047713382.USD","LU0128522744.USD","LU1820825898.SGD","BK0010","BK0187","LU1064130708.USD","LU1979443071.USD","LU0011963245.USD","SG9999000459.SGD","LU1934453819.USD","LU2328871848.SGD","LU0051755006.USD","LU2148510915.USD","HK0000181112.HKD","LU0210526637.USD","LU0543330566.HKD","LU1255011170.USD","BK0070","LU0708995153.HKD","LU1064131003.USD","LU0140636845.USD","LU1146622755.USD","LU2097828557.USD","LU2580892789.USD","LU0173614495.USD","600036","LU1781817850.SGD","BK0188","BK0012","LU1997245094.SGD","BK0015","LU0029874905.USD","LU1048596156.SGD","LU2097828714.EUR","SG9999001903.USD","LU2097828474.EUR","LU2097828631.EUR","02637","LU0287142896.SGD","LU2289578879.USD","SGXZ49509284.SGD","HK0000181138.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657975345","title":"Fujian Haixi Jumps on Initial Approval of Hx9428 for Macular Degeneration Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657975345","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657975345?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:52","pubTimestamp":1785905522,"startTime":"0","endTime":"0","summary":"BUZZ-Fujian Haixi jumps on initial approval of HX9428 for macular degeneration treatment** Shares of Fujian Haixi Pharmaceuticals2637.HKjump 14.5% in the fourth straight rising session to HK$213.4, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N44205H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158428386","title":"Haixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428","url":"https://stock-news.laohu8.com/highlight/detail?id=1158428386","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158428386?lang=en_us&edition=fundamental","pubTime":"2026-08-05 10:30","pubTimestamp":1785897057,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) shares jumped more than 14% in early trading, before settling to a gain of 5.42% at HK$196.40, with a trading volume of HK$21.28 million.The company announced that its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161078020","title":"Haixi Pharma secures FDA clearance for HX9428 Phase II nAMD trial and launches parallel study in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1161078020","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161078020?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:45","pubTimestamp":1785836742,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) has received U.S. Food and Drug Administration (FDA) approval to begin a Phase II clinical trial of its oral candidate HX9428 (also known as...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157694686","title":"HAIXI PHARMA Advances Oral nAMD Treatment with FDA Trial Approval and New Chinese Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1157694686","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157694686?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:20","pubTimestamp":1785835221,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that the U.S. Investigational New Drug (IND) application for its internally developed drug candidate, HX9428, has been approved by the U.S. Food and Drug Administration...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","02637","BK4585","LABU","BK4588","BK1191","PSYK","BMED","IBBJ","IND","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656853990","title":"Fujian Haixi Pharma Wins FDA IND Clearance for Hx9428 Phase II nAMD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656853990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656853990?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:13","pubTimestamp":1785834780,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trialFujian Haixi Pharmaceuticals secured US FDA IND clearance to start a Phase II trial of oral nAMD candidate HX9428 in the US.Chi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL356fXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4585","LU2468319806.SGD","LU0289739699.SGD","LU2089984988.USD","LU0823434583.USD","LU0882574055.USD","LU1974910355.USD","TBXU","LU2362541513.USD","LU0109394709.USD","LU2023250504.SGD","BBH","REGN","02637","LU0114720955.EUR","LU2237438978.USD","LU2362541273.HKD","LU0320765992.SGD","BK4588","LU0889565916.HKD","IBBQ","LU0058720904.USD","LU2362540622.SGD","LU0823416689.USD","LU0823434740.USD","LU0053666078.USD","LU1917777945.USD","IBB","LU2106854487.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399215","title":"Fujian Haixi Pharmaceuticals Co - U.S. FDA Approves Ind Application of Hx9428 for Neovascular Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399215?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:12","pubTimestamp":1785834779,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4401O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":79,"code":"91000000","status":"200"}]}}